Clinical Trial Update: Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for crenolanib in recurrent/refractory glioblastoma with PDGFRA amplification has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Recurrent/Refractory Glioblastoma | Phase 2 | Status: COMPLETED